MCID: OCL009
MIFTS: 59

Ocular Cancer

Categories: Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Ocular Cancer

MalaCards integrated aliases for Ocular Cancer:

Name: Ocular Cancer 12 15
Eye Carcinoma 12 15 72
Eye Neoplasms 44 72
Eye Neoplasm 12 17
Eye Cancer 55 43
Malignant Eye Neoplasm 12
Neoplasm of Eye Proper 12
Malignant Tumor of Eye 72
Carcinoma of Eye 12
Ocular Carcinoma 12
Neoplasm of Eye 12
Ocular Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2174 DOID:295
ICD9CM 35 190.8
MeSH 44 D005134
NCIt 50 C3030 C6079
ICD10 33 C69.9
UMLS 72 C0015414 C0153632 C0496836 more

Summaries for Ocular Cancer

MedlinePlus : 43 Cancer of the eye is uncommon. It can affect the outer parts of the eye, such as the eyelid, which are made up of muscles, skin and nerves. If the cancer starts inside the eyeball it's called intraocular cancer. The most common intraocular cancers in adults are melanoma and lymphoma. The most common eye cancer in children is retinoblastoma, which starts in the cells of the retina. Cancer can also spread to the eye from other parts of the body. Treatment for eye cancer varies by the type and by how advanced it is. It may include surgery, radiation therapy, freezing or heat therapy, or laser therapy.

MalaCards based summary : Ocular Cancer, also known as eye carcinoma, is related to grade iii astrocytoma and supratentorial cancer, and has symptoms including eye manifestations An important gene associated with Ocular Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are ERK Signaling and Gene Expression. The drugs Carmustine and Mesna have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and colon, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An ocular cancer that has material basis in abnormally proliferating cells, derives from epithelial cells and arises from the tissues that cover structures located in the eye.

Wikipedia : 75 Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer).... more...

Related Diseases for Ocular Cancer

Diseases related to Ocular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 268)
# Related Disease Score Top Affiliating Genes
1 grade iii astrocytoma 30.9 TP53 MDM2 CDKN2A CDK4
2 supratentorial cancer 30.8 TP53 SOX2 MDM2 CDKN2A
3 central nervous system cancer 30.8 TP53 SOX2 MYC CDKN2A
4 unilateral retinoblastoma 30.4 RBL1 RB1
5 melanoma, uveal 30.4 MC1R CDKN2A CDK4
6 venous hemangioma 30.3 SOX2 POU5F1 MYC
7 leiomyosarcoma 30.2 TP53 MDM2 CDK4
8 skin melanoma 30.1 TP53 MDM2 CDKN2A CDKN1A
9 teratoma 30.1 TP53 SOX2 POU5F1
10 medulloblastoma 30.0 TP53 SOX2 MYC CDK6 CDK4 CCND1
11 squamous cell carcinoma 30.0 TP53 RB1 CDKN2A CCND1 CCNA2
12 papilloma 30.0 TP53 RB1 CDKN2A CDKN1A CCND1
13 adenocarcinoma 29.8 TP53 RB1 MYC CDKN2A CDK4 CCND1
14 nasopharyngeal carcinoma 29.7 TP53 MYC MDM2 CDKN2A CDK4 CCND1
15 lung cancer susceptibility 3 29.7 TP53 CDKN2A CDKN1A CDK4 CCND1
16 sarcoma 29.7 TP53 RB1 POU5F1 MDM2 CDK6 CDK4
17 brain cancer 29.6 TP53 SOX2 RB1 POU5F1 MYC MDM2
18 bladder cancer 29.2 TP53 RB1 MYC MDM2 CDKN2A CDKN1A
19 pancreatic cancer 29.1 TP53 CDKN2A CDKN1A CDK6 CDK4 CCND1
20 glioma 29.0 TP53 MDM2 CDKN2A CDKN1A CDK6 CDK4
21 retinoblastoma 28.7 TP53 RBL1 RB1 MDM2 E2F4 E2F1
22 ewing sarcoma 28.6 TP53 SOX2 RB1 POU5F1 MYC MDM2
23 retinal cancer 28.6 TP53 RBL1 RB1 MYC MDM2 E2F4
24 glioblastoma multiforme 28.2 TP53 RB1 MYC MDM2 E2F1 CDKN2A
25 glioblastoma 28.0 TP53 RB1 MYC MDM2 E2F1 CDKN2A
26 breast cancer 27.8 TP53 RB1 MYC MDM2 E2F1 CDKN1A
27 eye carcinoma in situ 12.2
28 ocular melanoma 11.3
29 encephalocraniocutaneous lipomatosis 11.2
30 intraocular lymphoma 11.0
31 orbital cancer 11.0
32 xeroderma pigmentosum, variant type 10.9
33 bap1 tumor predisposition syndrome 10.9
34 vulvar adenocarcinoma 10.8 TP53 RB1
35 zika virus infection 10.8 TP53 MDM2
36 spindle cell lipoma 10.8 RB1 MDM2 CDK4
37 malignant fibrous histiocytoma of bone 10.8 MYC MDM2 CDK4
38 ring chromosome 7 10.8 TP53 MDM2 CDK4
39 breast papillomatosis 10.7 CDKN2A CCND1
40 infiltrating angiolipoma 10.7 MDM2 CDKN2A CDK4
41 periosteal osteogenic sarcoma 10.7 TP53 MDM2 CDK4
42 glioblastoma proneural subtype 10.7 CDK6 CDK4
43 small cell sarcoma 10.7 TP53 MDM2 CDK4
44 undifferentiated embryonal sarcoma of the liver 10.7 MDM2 CDK4
45 ewing's family of tumors 10.7 RB1 CDKN2A CDK4
46 well-differentiated liposarcoma 10.7 MDM2 CDKN2A CDK4
47 male reproductive system disease 10.7 TP53 MYC CCND1
48 synchronous bilateral breast carcinoma 10.7 TP53 CCND1 BRCA2
49 embryonal sarcoma 10.7 TP53 MDM2 CDK4
50 fallopian tube carcinoma 10.7 TP53 MYC BRCA2

Graphical network of the top 20 diseases related to Ocular Cancer:



Diseases related to Ocular Cancer

Symptoms & Phenotypes for Ocular Cancer

UMLS symptoms related to Ocular Cancer:


eye manifestations

GenomeRNAi Phenotypes related to Ocular Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.28 CDK6 CDKN2A E2F1 MYC RBL1 SOX2
2 Decreased viability GR00221-A-2 10.28 CDK6 E2F1 RBL1
3 Decreased viability GR00221-A-3 10.28 CDKN2A MYC
4 Decreased viability GR00221-A-4 10.28 CDK6 CDKN2A SOX2
5 Decreased viability GR00301-A 10.28 CDK6
6 Decreased viability GR00402-S-2 10.28 CDK6 CDKN2A E2F1 MYC RBL1 SOX2
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.13 BRCA2 CDK2 CDKN1A CDKN2A E2F1 RB1
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.13 BRCA2 CDK2 CDKN1A CDKN2A E2F1 RB1
9 Increased cell death HMECs cells GR00103-A-0 9.63 CCNA2 CDK2 E2F4 MDM2 MYC TP53
10 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRCA2 CDK2 CDK4 CDK6 RBL1

MGI Mouse Phenotypes related to Ocular Cancer:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.6 ABCG2 BRCA2 CCNA2 CCND1 CDK2 CDK4
2 behavior/neurological MP:0005386 10.54 ABCG2 BRCA2 CCND1 CDK4 CDKN1A CDKN2A
3 hematopoietic system MP:0005397 10.53 ABCG2 BRCA2 CCNA2 CCND1 CDK2 CDK4
4 embryo MP:0005380 10.51 BRCA2 CCNA2 CDK2 CDK4 CDK6 CDKN1A
5 immune system MP:0005387 10.51 ABCG2 BRCA2 CCNA2 CCND1 CDK2 CDK4
6 endocrine/exocrine gland MP:0005379 10.5 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
7 growth/size/body region MP:0005378 10.49 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
8 integument MP:0010771 10.48 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDKN1A
9 homeostasis/metabolism MP:0005376 10.47 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDKN1A
10 digestive/alimentary MP:0005381 10.46 BRCA2 CCND1 CDK4 CDKN1A CDKN2A E2F1
11 cardiovascular system MP:0005385 10.44 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
12 mortality/aging MP:0010768 10.44 BRCA2 CCNA2 CCND1 CDK2 CDK4 CDK6
13 neoplasm MP:0002006 10.38 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
14 craniofacial MP:0005382 10.36 CCND1 CDKN1A E2F1 E2F4 MC1R MDM2
15 liver/biliary system MP:0005370 10.3 ABCG2 CDK2 CDK4 CDK6 CDKN1A CDKN2A
16 nervous system MP:0003631 10.3 ABCG2 BRCA2 CCND1 CDK4 CDKN1A CDKN2A
17 muscle MP:0005369 10.27 CDK2 CDK4 CDK6 CDKN1A CDKN2A E2F1
18 hearing/vestibular/ear MP:0005377 10.24 CDKN1A E2F1 E2F4 MC1R MYC RB1
19 normal MP:0002873 10.22 ABCG2 BRCA2 CCND1 CDK4 E2F1 E2F4
20 adipose tissue MP:0005375 10.18 ABCG2 CDKN1A E2F1 MYC RB1 RBL1
21 reproductive system MP:0005389 10.16 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
22 limbs/digits/tail MP:0005371 10.14 BRCA2 CDKN1A MC1R MDM2 MYC RB1
23 no phenotypic analysis MP:0003012 10.09 CDKN1A CDKN2A MC1R MDM2 MYC RB1
24 pigmentation MP:0001186 9.97 CDK4 CDKN2A MC1R MDM2 MYC RB1
25 renal/urinary system MP:0005367 9.87 ABCG2 CDK4 CDKN1A MDM2 RB1 RBL1
26 respiratory system MP:0005388 9.81 CCND1 CDKN1A CDKN2A E2F1 E2F4 RB1
27 skeleton MP:0005390 9.73 BRCA2 CCND1 CDKN1A CDKN2A E2F1 E2F4
28 vision/eye MP:0005391 9.32 CCND1 CDK2 CDK4 CDKN1A CDKN2A E2F1

Drugs & Therapeutics for Ocular Cancer

Drugs for Ocular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3 154-93-8 2578
2
Mesna Approved, Investigational Phase 3 3375-50-6 598
3
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
7
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
8
Lenograstim Approved, Investigational Phase 3 135968-09-1
9
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
10 O(6)-benzylguanine Phase 3
11 Anesthetics Phase 3
12 Antirheumatic Agents Phase 3
13 Immunologic Factors Phase 3
14 Alkylating Agents Phase 3
15 Immunosuppressive Agents Phase 3
16 Antineoplastic Agents, Alkylating Phase 3
17 Tubulin Modulators Phase 3
18
Liposomal doxorubicin Phase 3 31703
19 Antineoplastic Agents, Phytogenic Phase 3
20 Anti-Bacterial Agents Phase 3
21 Antibiotics, Antitubercular Phase 3
22 Topoisomerase Inhibitors Phase 3
23 topoisomerase I inhibitors Phase 3
24 Etoposide phosphate Phase 3
25 Antimitotic Agents Phase 3
26
Tramadol Approved, Investigational Phase 1, Phase 2 27203-92-5 33741
27
Ibuprofen Approved Phase 1, Phase 2 15687-27-1 3672
28
Guaifenesin Approved, Investigational, Vet_approved Phase 1, Phase 2 93-14-1 3516
29
Methadone Approved, Illicit Phase 1, Phase 2 76-99-3 4095
30
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
31
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
32
Melphalan Approved Phase 2 148-82-3 460612 4053
33 Anti-Inflammatory Agents Phase 1, Phase 2
34 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
35 Cyclooxygenase Inhibitors Phase 1, Phase 2
36 Narcotics Phase 1, Phase 2
37 Analgesics Phase 1, Phase 2
38 D-methadone Phase 1, Phase 2
39 Peripheral Nervous System Agents Phase 1, Phase 2
40 Analgesics, Opioid Phase 1, Phase 2
41 Respiratory System Agents Phase 1, Phase 2
42 Chlorpheniramine, phenylpropanolamine drug combination Phase 1, Phase 2
43 Analgesics, Non-Narcotic Phase 1, Phase 2
44 Antitussive Agents Phase 1, Phase 2
45 Fertility Agents Phase 2
46 Antineoplastic Agents, Hormonal Phase 2
47 Vaccines Phase 2
48 Technetium Tc 99m Sulfur Colloid Phase 2
49 Radiopharmaceuticals Phase 2
50
rituximab Approved Phase 1 174722-31-7 10201696

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
2 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
3 Protocol for the Study and Treatment of Patients With Intraocular Retinoblastoma Active, not recruiting NCT00186888 Phase 3 Vincristine, Carboplatin;Vincristine and Topotecan;Vincristine + Carboplatin + Etoposide;vincristine, cyclophosphamide, and doxorubicin;Vincristine, Carboplatin and Etoposide
4 Post-Operative Pain Relief Following Insertion of Radioactive Plaque for Choroidal Melanoma: Randomised Control Trial of Tramadol Vs Ibuprofen: A Pilot Study Unknown status NCT00111046 Phase 1, Phase 2 Ibuprofen;Tramadol
5 A Phase I/II Study of D-Methadone in Patients With Chronic Pain Completed NCT00588640 Phase 1, Phase 2 d-Methadone;D-methadone;placebo
6 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan Followed by Temozolomide for Subjects With Unresectable Hepatic Metastases From Ocular Melanoma Completed NCT00062933 Phase 2
7 Study of the Modulatory Activity of an LHRH-Agonist (Leuprolide) on Melanoma Peptide Vaccines as Adjuvant Therapy in Melanoma Patients Completed NCT00254397 Phase 2 Leuprolide
8 Sentinel Lymph Node Localization and Biopsy for Sebaceous Gland Carcinoma of the Eyelid Recruiting NCT00832429 Phase 2 Tc99m-Sulfur colloid
9 A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma Recruiting NCT03052127 Phase 1, Phase 2 Light-activated AU-011
10 Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases: a Randomized Phase II Clinical Trial Active, not recruiting NCT03028337 Phase 2
11 An Open, Single-centre Non-randomized Phase II Clinical Trial on Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Terminated NCT01393769 Phase 2 Melphalan
12 Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Withdrawn NCT01151748 Phase 2
13 Intravitreal Rituximab Completed NCT02332941 Phase 1 Rituximab
14 A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors Recruiting NCT03435952 Phase 1 Pembrolizumab;Doxycycline
15 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
16 Postoperative Pain of General Anesthesia in Orbital Disease and Ocular Tumor Unknown status NCT02704715
17 Epidemiologic, Laboratory, and Clinical Characterization of Individuals With Ocular Diseases Unknown status NCT00249392
18 Quality of Life of Eye Amputated Patients in Denmark Completed NCT01072253
19 Social-Psychological Aspects of Survivorship in Cancer Patients After Orbital Exenteration: Issues Stemming From Alterations of Normal Facial Appearance Completed NCT00601744
20 New Biopsy Technique for Uveal Melanoma Completed NCT01924923
21 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
22 Dynamic Contrast Enhanced Magnetic Resonance Imaging for Non-Invasive Diagnostic Work-Up in Solid Tumors of the Eye and Orbit. Recruiting NCT01653080
23 The Role of Inflammation in Ocular Tumours Recruiting NCT02909517
24 Early Non-Invasive Ventilation in Patients With Hypoxemic Respiratory Failure and Hematological Malignancies: A Prospective Randomized Controlled Trial Recruiting NCT02464696
25 Smartphone Screening for Eye Diseases Enrolling by invitation NCT03076697
26 Determine the Effects of Selenium and Melatonin on Ocular Ischemic Syndrome Not yet recruiting NCT04005222 Early Phase 1 SELENIUM;MELATONIN

Search NIH Clinical Center for Ocular Cancer

Cochrane evidence based reviews: eye neoplasms

Genetic Tests for Ocular Cancer

Anatomical Context for Ocular Cancer

MalaCards organs/tissues related to Ocular Cancer:

41
Eye, Skin, Colon, Bone, Kidney, Bone Marrow, Retina

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Cancer:

19
Eye

Publications for Ocular Cancer

Articles related to Ocular Cancer:

(show top 50) (show all 83)
# Title Authors PMID Year
1
Neurofibromatosis type 1 with tarsal conjunctiva thickening: A case report. 17
31374061 2019
2
Intraocular medulloepithelioma - A review of clinical features, DICER 1 mutation, and management. 17
31124483 2019
3
A Review of the Role of Cytogenetics in the Diagnosis of Orbital Rhabdomyosarcoma. 17
31146616 2019
4
Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. 38
31200439 2019
5
Contemporary management of retinoblastoma in the context of a low-resource country. 38
31187745 2019
6
The Amazon Ocular Oncology Center: The first three years. 38
30698230 2019
7
Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference. 38
30652059 2019
8
Retinoblastoma, the visible CNS tumor: A review. 38
29314142 2019
9
Membrane Proteome of Invasive Retinoblastoma: Differential Proteins and Biomarkers. 38
29742327 2018
10
The distinguished Austrian ophthalmologist Ernst Fuchs (1851-1930) and the "sarcom des uvealtractus". 38
30570892 2018
11
Imaging Techniques in the Diagnosis and Management of Ocular Tumors: Prospects and Challenges. 38
30187172 2018
12
Preimplantation genetic diagnosis as a strategy to prevent having a child born with an heritable eye disease. 38
29781739 2018
13
Wilhelm Fabricius von Hilden (1560-1634): The Pioneer of German Surgery. 38
29473453 2018
14
The distinguished Greek born, French ophthalmologist Photinos Panas (1832-1903) and his views on ocular cancer. 38
30003766 2018
15
Gamma irradiation of ocular melanoma and lymphoma cells in the presence of gold nanoparticles: in vitro study. 38
29707895 2018
16
Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies. 38
29593251 2018
17
The management of retinoblastoma. 38
29321667 2018
18
Antonio Scarpa (1752-1832) and his study on ocular cancer. 38
29552793 2018
19
Molecular Characteristics of Conjunctival Melanoma Using Whole-Exome Sequencing. 38
29121185 2017
20
Technical Note: Dosimetric characteristics of the ocular beam line and commissioning data for an ocular proton therapy planning system at the Proton Therapy Center Houston. 38
28975637 2017
21
Characterization of Eyeball Loss in Four Cities of Colombia. 38
29152434 2017
22
RB1 gene mutations in Argentine retinoblastoma patients. Implications for genetic counseling. 38
29261756 2017
23
The beginning of using X-rays and the evolution of equipment for the treatment of ocular cancer. 38
28315914 2017
24
Medical History in the Hellenic Journal of Nuclear Medicine. 38
28426839 2017
25
Absent MicroRNAs in Different Tissues of Patients with Acquired Cardiomyopathy. 38
27475403 2016
26
WO3/Pt nanoparticles promote light-induced lipid peroxidation and lysosomal instability within tumor cells. 38
26788907 2016
27
Views on ocular cancer in Arabo-Islamic medicine and the leading influence of the ancient Greek medicine. 38
27061559 2016
28
Global gene deregulations in FASN silenced retinoblastoma cancer cells: molecular and clinico-pathological correlations. 38
25958981 2015
29
Drosophila as a Potential Model for Ocular Tumors. 38
27172095 2015
30
[Epidemiological and clinical characteristics of primary ocular cancers in blacks: our experience with 111 cases]. 38
25530349 2015
31
Nanoparticle-aided Radiotherapy for Retinoblastoma and Choroidal Melanoma. 38
28003818 2015
32
Chebulagic acid from Terminalia chebula causes G1 arrest, inhibits NFκB and induces apoptosis in retinoblastoma cells. 38
25169718 2014
33
The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): overview and results of the research prioritisation survey process. 38
25056971 2014
34
Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients. 38
24417420 2014
35
Uveal melanoma: A pathologist's perspective and review of translational developments. 38
24508696 2014
36
MicroRNA-21 Down-regulates Rb1 Expression by Targeting PDCD4 in Retinoblastoma. 38
25520758 2014
37
Local chemotherapeutic agents for the treatment of ocular malignancies. 38
24112549 2014
38
Abnormal odontogenesis following management of childhood cancer (retinoblastoma): review and a new variant. 38
23811674 2013
39
The pathology of ocular cancer. 38
23154492 2013
40
Molecular Insights on Post-chemotherapy Retinoblastoma by Microarray Gene Expression Analysis. 38
24092970 2013
41
Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells. 38
23441619 2013
42
Microarray analysis and biochemical correlations of oxidative stress responsive genes in retinoblastoma. 38
22668346 2012
43
[The application of serum free medium in the research of isolating cancer stem cells]. 38
23141583 2012
44
The absence of Brm exacerbates photocarcinogenesis. 38
22775994 2012
45
Therapeutic and toxicologic evaluation of anti-lipogenic agents in cancer cells compared with non-neoplastic cells. 38
22151915 2012
46
Advances in hydrogels applied to degenerative diseases. 38
22512441 2012
47
Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells. 38
23181152 2010
48
Awareness and knowledge of ocular cancers in a resource-limited economy. 38
22558560 2010
49
Retinoblastoma Registry report--Hospital Kuala Lumpur experience. 38
21488473 2010
50
Id2 deficiency promotes metastasis in a mouse model of ocular cancer. 38
20127274 2010

Variations for Ocular Cancer

Cosmic variations for Ocular Cancer:

9 (show all 45)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM891 RB1 eye,retina,retinoblastoma,NS c.958C>T p.R320* 13:48367512-48367512 36
2 COSM877 RB1 eye,retina,retinoblastoma,NS c.341C>A p.S114* 13:48342675-48342675 36
3 COSM910 RB1 eye,retina,retinoblastoma,NS c.1467C>A p.C489* 13:48380210-48380210 36
4 COSM895 RB1 eye,retina,retinoblastoma,NS c.1363C>T p.R455* 13:48379624-48379624 36
5 COSM1015 RB1 eye,retina,retinoblastoma,NS c.1215+1G>A p.? 13:48373493-48373493 36
6 COSM943 RB1 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 36
7 COSM13117 RB1 eye,retina,retinoblastoma,NS c.2053C>T p.Q685* 13:48459780-48459780 36
8 COSM1636648 RB1 eye,retina,retinoblastoma,NS c.2106+2T>G p.? 13:48459835-48459835 36
9 COSM1014 RB1 eye,retina,retinoblastoma,NS c.1216-2A>G p.? 13:48376916-48376916 36
10 COSM888 RB1 eye,retina,retinoblastoma,NS c.1666C>T p.R556* 13:48381414-48381414 36
11 COSM938 RB1 eye,retina,retinoblastoma,NS c.967G>T p.E323* 13:48367521-48367521 36
12 COSM878 RB1 eye,retina,retinoblastoma,NS c.751C>T p.R251* 13:48362847-48362847 36
13 COSM887 RB1 eye,retina,retinoblastoma,NS c.1654C>T p.R552* 13:48381402-48381402 36
14 COSM317962 RB1 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 36
15 COSM903 RB1 eye,retina,retinoblastoma,NS c.1494T>A p.Y498* 13:48380237-48380237 36
16 COSM1026 RB1 eye,retina,retinoblastoma,NS c.2326-2A>C p.? 13:48465203-48465203 36
17 COSM876 RB1 eye,retina,retinoblastoma,NS c.160G>T p.E54* 13:48307302-48307302 36
18 COSM1013 RB1 eye,retina,retinoblastoma,NS c.1389+1G>C p.? 13:48379651-48379651 36
19 COSM1030 RB1 eye,retina,retinoblastoma,NS c.1961-1G>A p.? 13:48459687-48459687 36
20 COSM1040 RB1 eye,retina,retinoblastoma,NS c.1960+2T>C p.? 13:48456351-48456351 36
21 COSM890 RB1 eye,retina,retinoblastoma,NS c.409G>T p.E137* 13:48345108-48345108 36
22 COSM911 RB1 eye,retina,retinoblastoma,NS c.1166T>A p.L389* 13:48373443-48373443 36
23 COSM889 RB1 eye,retina,retinoblastoma,NS c.2158A>T p.K720* 13:48463782-48463782 36
24 COSM880 RB1 eye,retina,retinoblastoma,NS c.1333C>T p.R445* 13:48379594-48379594 36
25 COSM3724517 RB1 eye,retina,retinoblastoma,NS c.862-5T>G p.? 13:48364889-48364889 36
26 COSM3724518 RB1 eye,retina,retinoblastoma,NS c.2520+4A>G p.? 13:48473394-48473394 36
27 COSM936 RB1 eye,retina,retinoblastoma,NS c.1183C>T p.Q395* 13:48373460-48373460 36
28 COSM144722 RB1 eye,retina,retinoblastoma,NS c.265-2A>C p.? 13:48342597-48342597 36
29 COSM1047 RB1 eye,retina,retinoblastoma,NS c.982A>C p.N328H 13:48367536-48367536 36
30 COSM942 RB1 eye,retina,retinoblastoma,NS c.2063T>C p.L688P 13:48459790-48459790 36
31 COSM5700369 RB1 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 36
32 COSM1041 RB1 eye,retina,retinoblastoma,NS c.1049+1G>T p.? 13:48367604-48367604 36
33 COSM1017 RB1 eye,retina,retinoblastoma,NS c.380+1G>T p.? 13:48342715-48342715 36
34 COSM3724510 RB1 eye,retina,retinoblastoma,NS c.2527G>T p.E843* 13:48476707-48476707 36
35 COSM1050 RB1 eye,retina,retinoblastoma,NS c.1421G>A p.S474N 13:48380084-48380084 36
36 COSM5686463 RB1 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 36
37 COSM882 RB1 eye,retina,retinoblastoma,NS c.2152G>A p.D718N 13:48463776-48463776 36
38 COSM1016 RB1 eye,retina,retinoblastoma,NS c.1960+1G>A p.? 13:48456350-48456350 36
39 COSM764 PIK3CA eye,retina,retinoblastoma,NS c.1634A>G p.E545G 3:179218304-179218304 36
40 COSM521 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 12:25245350-25245350 36
41 COSM520 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 12:25245350-25245350 36
42 COSM5686462 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 36
43 COSM5668651 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 36
44 COSM5025108 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 36
45 COSM5700368 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 36

Expression for Ocular Cancer

Search GEO for disease gene expression data for Ocular Cancer.

Pathways for Ocular Cancer

Pathways related to Ocular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 TP53 SOX2 RBL1 RB1 MYC MDM2
2
Show member pathways
13.9 TP53 RBL1 MYC MDM2 E2F4 E2F1
3
Show member pathways
13.89 TP53 RB1 MYC MDM2 E2F4 E2F1
4
Show member pathways
13.65 TP53 RBL1 RB1 MYC MDM2 E2F4
5
Show member pathways
13.34 TP53 RB1 MDM2 E2F1 CDKN2A CDKN1A
6
Show member pathways
13.26 TP53 RBL1 RB1 MYC MDM2 E2F1
7
Show member pathways
13.22 TP53 RB1 MYC MDM2 E2F1 CDKN2A
8
Show member pathways
13.17 TP53 RBL1 MDM2 E2F4 E2F1 CDKN2A
9
Show member pathways
13.12 TP53 RB1 MYC MDM2 E2F1 CDKN2A
10 13.09 TP53 RB1 MYC MDM2 E2F1 CDKN2A
11
Show member pathways
13.04 TP53 RB1 MYC E2F1 CDKN2A CDKN1A
12
Show member pathways
12.97 TP53 RB1 MDM2 E2F1 CDKN2A CDKN1A
13
Show member pathways
12.87 TP53 MYC MDM2 CDKN2A CDKN1A
14 12.78 TP53 MYC MDM2 E2F1 CDKN2A CDKN1A
15
Show member pathways
12.73 TP53 MDM2 CDKN1A CDK2 CCNA2
16
Show member pathways
12.71 TP53 MYC MDM2 CDKN1A CCND1
17
Show member pathways
12.68 TP53 RBL1 RB1 MYC MDM2 E2F4
18 12.65 TP53 RBL1 RB1 MYC E2F4 E2F1
19 12.62 TP53 RB1 MYC E2F1 CDKN2A CDKN1A
20 12.62 TP53 RB1 MDM2 E2F1 CDKN2A CDKN1A
21
Show member pathways
12.59 SOX2 RB1 POU5F1 E2F4 E2F1
22
Show member pathways
12.57 TP53 RB1 MYC MDM2 E2F1 CDKN2A
23
Show member pathways
12.55 TP53 RB1 MDM2 E2F4 E2F1 CDKN1A
24 12.54 TP53 RBL1 RB1 MDM2 CDKN2A CDKN1A
25
Show member pathways
12.53 TP53 MYC MDM2 CDKN1A CCND1
26
Show member pathways
12.52 TP53 RBL1 RB1 MYC MDM2 E2F4
27
Show member pathways
12.49 TP53 CDKN1A CCND1 CCNA2
28
Show member pathways
12.49 TP53 RB1 CDKN1A CDK2 CCNA2
29
Show member pathways
12.49 TP53 RB1 MYC MDM2 E2F4 E2F1
30 12.45 TP53 MYC MDM2 CDKN1A CCND1
31 12.45 TP53 RB1 MYC MDM2 E2F1 CDK4
32
Show member pathways
12.45 TP53 RBL1 RB1 E2F4 E2F1 CDKN2A
33 12.44 TP53 MYC MDM2 E2F4 E2F1 CDKN1A
34
Show member pathways
12.42 RB1 MYC E2F4 E2F1 CDKN2A CDKN1A
35
Show member pathways
12.41 TP53 SOX2 POU5F1 MYC CCND1
36
Show member pathways
12.39 RB1 CDK6 CDK4 CDK2 CCND1 CCNA2
37 12.35 TP53 MYC E2F4 CDKN1A CCND1
38 12.34 TP53 MYC MDM2 CDKN1A
39 12.31 TP53 RBL1 MYC E2F4 CDKN1A CCND1
40 12.31 TP53 RB1 MDM2 E2F1 CDKN2A CDKN1A
41 12.3 TP53 RB1 MYC E2F1 CDK4 CDK2
42 12.24 RBL1 RB1 E2F4 E2F1 CDKN1A
43
Show member pathways
12.24 TP53 RBL1 RB1 MYC E2F4 E2F1
44 12.23 TP53 MYC MDM2 CDKN2A CDKN1A CCND1
45 12.23 TP53 RB1 MYC MDM2 E2F4 E2F1
46
Show member pathways
12.21 TP53 RBL1 E2F4 E2F1 CDKN1A CDK2
47
Show member pathways
12.2 MDM2 CDKN1A CDK2 CCND1
48 12.2 TP53 RB1 MDM2 E2F1 CDKN2A CDKN1A
49 12.18 TP53 RB1 MDM2 CDKN1A
50 12.18 TP53 SOX2 MYC CDKN1A CCND1

GO Terms for Ocular Cancer

Cellular components related to Ocular Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 centrosome GO:0005813 9.89 TCHP E2F1 CDK6 CDK2 BRCA2
2 nucleoplasm GO:0005654 9.89 TP53 SOX2 RBL1 RB1 POU5F1 MYC
3 protein-containing complex GO:0032991 9.87 TP53 MYC MDM2 E2F1 CDKN1A CDK4
4 nuclear chromatin GO:0000790 9.77 TP53 POU5F1 MYC E2F4 E2F1
5 transcription factor complex GO:0005667 9.7 SOX2 RBL1 RB1 E2F4 E2F1 CDK4
6 Rb-E2F complex GO:0035189 9.43 RB1 E2F1
7 cyclin A2-CDK2 complex GO:0097124 9.4 CDK2 CCNA2
8 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.1 CDKN1A CDK6 CDK4 CDK2 CCND1 CCNA2
9 cytoplasm GO:0005737 10.33 TP53 TCHP SOX2 POU5F1 MYC MDM2
10 cytosol GO:0005829 10.29 TP53 TCHP SOX2 POU5F1 MDM2 CDKN2A
11 nucleus GO:0005634 10.21 TP53 SOX2 RBL1 RB1 POU5F1 MYC

Biological processes related to Ocular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 regulation of gene expression GO:0010468 9.99 SOX2 POU5F1 MYC MDM2 CDK6 CDK4
2 regulation of cell cycle GO:0051726 9.98 RBL1 RB1 E2F4 E2F1 CDK4 CDK2
3 response to drug GO:0042493 9.97 MYC MDM2 CDKN1A CDK4 CCND1
4 cellular response to hypoxia GO:0071456 9.95 TP53 MYC MDM2 E2F1 CCNA2
5 negative regulation of cell growth GO:0030308 9.93 TP53 TCHP CDKN2A CDKN1A
6 cell cycle arrest GO:0007050 9.91 TP53 SOX2 RB1 MYC CDKN2A CDKN1A
7 response to toxic substance GO:0009636 9.9 MDM2 CDKN1A CDK4
8 response to organic substance GO:0010033 9.89 CDKN1A CDK4 CCND1
9 regulation of signal transduction by p53 class mediator GO:1901796 9.88 TP53 MDM2 CDK2
10 response to wounding GO:0009611 9.88 SOX2 POU5F1 MYC
11 Ras protein signal transduction GO:0007265 9.88 TP53 RB1 CDKN2A CDKN1A CDK2 CCNA2
12 cellular response to organic cyclic compound GO:0071407 9.87 MYC MDM2 CCNA2
13 negative regulation of epithelial cell proliferation GO:0050680 9.86 SOX2 RB1 CDK6
14 animal organ regeneration GO:0031100 9.86 CDKN1A CDK4 CCND1 CCNA2
15 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.85 RBL1 RB1 CDKN1A
16 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.85 CDKN1A CCND1 CCNA2
17 regulation of mitotic cell cycle GO:0007346 9.83 RBL1 RB1 MYC CDKN1A
18 response to gamma radiation GO:0010332 9.8 TP53 MYC BRCA2
19 response to estradiol GO:0032355 9.8 MYC CCND1 CCNA2
20 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.8 TP53 MDM2 E2F4 E2F1 CDKN1A CDK2
21 negative regulation of cell cycle arrest GO:0071157 9.78 MDM2 CDK4 CCND1
22 positive regulation of cell cycle GO:0045787 9.78 MYC MDM2 CDK4 CCND1
23 response to X-ray GO:0010165 9.77 CDKN1A CCND1 BRCA2
24 replicative senescence GO:0090399 9.75 TP53 CDKN2A CDKN1A
25 response to hyperoxia GO:0055093 9.72 CDKN1A CDK4
26 regulation of G1/S transition of mitotic cell cycle GO:2000045 9.72 E2F1 CCND1
27 response to magnesium ion GO:0032026 9.71 MDM2 CCND1
28 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.71 TP53 BRCA2
29 histone phosphorylation GO:0016572 9.71 CDK2 CCNA2
30 mitotic G1 DNA damage checkpoint GO:0031571 9.71 TP53 CDK2 CCND1
31 amyloid fibril formation GO:1990000 9.7 MDM2 CDKN2A
32 negative regulation of monocyte differentiation GO:0045656 9.68 MYC CDK6
33 re-entry into mitotic cell cycle GO:0000320 9.68 MYC CCND1
34 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.68 MYC CDK4
35 signal transduction by p53 class mediator GO:0072331 9.67 TP53 CDKN1A
36 endodermal cell fate specification GO:0001714 9.67 SOX2 POU5F1
37 cellular response to xenobiotic stimulus GO:0071466 9.66 RB1 E2F1
38 transcription by RNA polymerase II GO:0006366 9.66 POU5F1 MYC
39 regulation of lipid kinase activity GO:0043550 9.65 RBL1 RB1
40 negative regulation of transcription involved in G1/S transition of mitotic cell cycle GO:0071930 9.65 RB1 E2F1
41 cellular response to actinomycin D GO:0072717 9.64 TP53 MDM2
42 positive regulation of fibroblast proliferation GO:0048146 9.63 MYC E2F1 CDKN1A CDK6 CDK4 CCNA2
43 G1/S transition of mitotic cell cycle GO:0000082 9.56 RB1 MYC CDKN2A CDKN1A CDK6 CDK4
44 cell cycle GO:0007049 9.44 TP53 RBL1 RB1 E2F4 E2F1 CDKN2A
45 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 TP53 SOX2 RBL1 RB1 POU5F1 MYC
46 positive regulation of transcription, DNA-templated GO:0045893 10.11 TP53 SOX2 RB1 MYC E2F1 CDKN2A
47 viral process GO:0016032 10.09 TP53 RBL1 RB1 MDM2 CCNA2
48 negative regulation of cell proliferation GO:0008285 10.09 TP53 RB1 CDKN2A CDKN1A CDK6
49 cellular response to DNA damage stimulus GO:0006974 10.09 TP53 MYC CDKN1A CDK2 CCND1 BRCA2
50 positive regulation of gene expression GO:0010628 10.08 TP53 POU5F1 MYC MDM2 E2F1 CDKN2A

Molecular functions related to Ocular Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.96 CDK6 CDK4 CDK2 CCND1 CCNA2
2 protein domain specific binding GO:0019904 9.85 MDM2 E2F4 CDK2 CCNA2
3 protein kinase binding GO:0019901 9.85 TP53 E2F1 CDKN2A CDKN1A CCND1 CCNA2
4 ubiquitin protein ligase binding GO:0031625 9.8 TP53 RB1 POU5F1 MDM2 MC1R CDKN1A
5 promoter-specific chromatin binding GO:1990841 9.67 TP53 RBL1 E2F4
6 cyclin-dependent protein serine/threonine kinase regulator activity GO:0016538 9.61 CDK4 CCND1 CCNA2
7 cyclin binding GO:0030332 9.58 CDK6 CDK4 CDK2
8 disordered domain specific binding GO:0097718 9.56 TP53 RB1 MDM2 CDKN2A
9 transcription factor binding GO:0008134 9.56 TP53 RBL1 RB1 MYC E2F4 E2F1
10 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.54 CDKN2A CDKN1A
11 RNA polymerase II regulatory region DNA binding GO:0001012 9.52 RBL1 RB1
12 cyclin-dependent protein kinase activity GO:0097472 9.48 CDK2 CCNA2
13 cyclin-dependent protein serine/threonine kinase activity GO:0004693 8.8 CDK6 CDK4 CDK2
14 DNA binding GO:0003677 10.16 TP53 SOX2 RB1 POU5F1 MYC E2F4
15 protein binding GO:0005515 10.16 TP53 TCHP SOX2 RBL1 RB1 POU5F1
16 DNA-binding transcription factor activity GO:0003700 10 TP53 SOX2 RB1 POU5F1 MYC E2F4

Sources for Ocular Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....